In order to promote the implementation of Chinese medicine products and medical services, the two companies have joined forces

On December 31, Yiling Pharmaceutical issued an announcement stating that the company signed a cooperation framework agreement with Shun Teng International (Holdings) Co.
, Ltd.
on December 30 to formally develop cross-border e-commerce platforms, product registration and sales, and medical services.
Cooperation
.
It is understood that Shun Teng International and its subsidiaries are mainly engaged in the formulation, promotion, sales and distribution of Chinese medicine and health care and beauty supplements and products in Hong Kong, and provide online e-commerce promotion business in Greater China
.
At present, it has eight proprietary brands and one distribution agent's own brand, and produces a total of about 159 Chinese patent medicines, health products, beauty and slimming products
.
According to the announcement, after the cooperation between the two parties, Yiling Pharmaceuticals will use its resource advantages in retail channels to introduce Shun Teng International products for sale in mainland China
.
At the same time, Shun Teng International will assist Yiling Pharmaceutical in the registration of patented Chinese medicine products in Hong Kong, and use its current strategic cooperation in Hong Kong to distribute agent store partners, a total of approximately 550 physical stores and approximately 50 stores with in-store promoters.
Based on special counters, Yiling Pharmaceutical's patented Chinese medicine products are sold
.
In addition, Yiling Pharmaceuticals will also cooperate with Shun Teng International to establish a medical service center in Hong Kong, combining medical resources in the Mainland to promote high-quality Chinese medicine services in the Mainland through remote medical treatment, on-site medical consultation and diagnosis, Chinese medicine prescription and dispensing services, etc.
Implementation in Hong Kong
.
In fact, this cooperation is not alone
.
Since its establishment, Yiling Pharmaceutical has always adhered to the concept of "Technological innovation is the core competitiveness of the enterprise", and has always been committed to continuous research on the prevention and treatment of cardiovascular and cerebrovascular diseases, respiratory diseases, diabetes, tumors and other diseases with Tongluo Chinese medicine
.
In recent years, in order to promote the continuous implementation of traditional Chinese medicine products and medical services, it has actively cooperated with many companies
.
For example, from September 3 to 5, 2020, Yiling Pharmaceutical and Gaoji Medical signed a 2020-2021 strategic cooperation framework agreement
.
According to the announcement, the two parties will complement each other's strengths, and will carry out in-depth cooperation in many areas such as chronic disease projects, Internet hospitals, diabetes, Lianhua strategic supply guarantee, and Chinese herbal medicines.

.
With these cooperations, Yiling Pharmaceutical currently has a very dazzling performance in new drug research and development, market development, and wide product coverage
.
For example, while Yiling Pharmaceuticals continues to promote the innovation of traditional Chinese medicine products, its performance continues to improve
.
According to data from the third quarter report, Yiling Pharmaceutical achieved revenue of 8.
112 billion yuan in the first three quarters of 2021, an increase of 25.
81% year-on-year; net profit attributable to the parent company was 1.
224 billion yuan, an increase of 20.
43% year-on-year; of which, the third quarter contributed revenue of 2.
216 billion yuan.
, A year-on-year increase of 13.
01%; net profit of 260 million yuan
.
With the current national policy vigorously advancing the development of the Chinese medicine industry, the industry expects that Yiling Pharmaceutical will usher in new development opportunities
.
With the development advantages of maintaining technological innovation, Yiling Pharmaceutical will continue to contribute more and more important forces to the promotion of the modernization, industrialization, and internationalization of Chinese medicine, and the promotion of the revitalization and development of Chinese medicine in the future
.